相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study
Francesca Palandri et al.
ANNALS OF HEMATOLOGY (2011)
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Juergen Thiele et al.
BLOOD (2011)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
Tiziano Barbui et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Giovanni Barosi et al.
BLOOD (2009)
Leukocytosis at Diagnosis and the Risk of Subsequent Thrombosis in Patients With Low-Risk Essential Thrombocythemia and Polycythemia Vera
Naseema Gangat et al.
CANCER (2009)
Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy
Peter J. Campbell et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia
F. Passamonti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
Federico Lussana et al.
THROMBOSIS RESEARCH (2009)
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease
Sophie Lanzkron et al.
ANNALS OF INTERNAL MEDICINE (2008)
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
Marina Marchetti et al.
BLOOD (2008)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Leukocytosis and risk stratification assessment in essential thrombocythemia
Alessandra Carobbio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
G. Finazzi et al.
LEUKEMIA (2008)
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes
Bridget S. Wilkins et al.
BLOOD (2008)
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Annette H. Schmitt-Graeff et al.
HAEMATOLOGICA (2007)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Alessandra Carobbio et al.
BLOOD (2007)
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group
G. Barosi et al.
LEUKEMIA (2007)
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
Guido Finazzi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?
N. Maugeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?
Ayalew Tefferi et al.
BLOOD (2006)
Long-term effects of the treatment of polycythemia vera with recombinant interferon-α
Richard T. Silver
CANCER (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia
B Cheung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach
J Thiele et al.
SEMINARS IN HEMATOLOGY (2005)
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli et al.
LEUKEMIA (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
C Harrison
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders
SM Fruchtman et al.
LEUKEMIA RESEARCH (2005)
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
MA Elliott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis
G Finazzi et al.
BLOOD (2003)
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia
R Jantunen et al.
ANNALS OF HEMATOLOGY (2001)
A long-term retrospective study of young women with essential thrombocythemia
A Tefferi et al.
MAYO CLINIC PROCEEDINGS (2001)
分享论文
